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Abstract
Abnormal cellular growth and organization have been characterized in postmortem tissue from
brains of autistic individuals, suggestive of pathology in a critical neurogenic niche, the
subventricular zone (SVZ) of the brain lateral ventricles (LV). We examined cellular organization,
cell proliferation, and constituents of the extracellular matrix such as N-sulfated heparan sulfate
(HS) and laminin (LAM) in postmortem brain tissue from the LV-SVZ of young to elderly
individuals with autism (n = 4) and age-matched typically developing (TD) individuals (n = 4)
using immunofluorescence techniques. Strong and systematic reductions in HS
immunofluorescence were observed in the LV-SVZ of the TD individuals with increasing age. For
young through mature, but not elderly, autistic pair members, HS was reduced compared to their
matched TDs. Cellular proliferation (Ki67+) was higher in the autistic individual of the youngest
age-matched pair. These preliminary data suggesting that HS may be reduced in young to mature
autistic individuals are in agreement with previous findings from the BTBR T+tf/J mouse, an
animal model of autism; from mice with genetic modifications reducing HS; and with genetic
variants in HS-related genes in autism. They suggest that aberrant extracellular matrix
glycosaminoglycan function localized to the subventricular zone of the lateral ventricles may be a
biomarker for autism, and potentially involved in the etiology of the disorder.
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Autism spectrum disorders (ASD) are a heterogeneous group of behaviorally defined,
neurodevelopmental disorders [1]. Although there is strong evidence for genetic factors in
ASD, it appears to be a polygenic condition [2, 3], and also responsive to a range of
environmental/experiential events [4, 5]. Thus, its precise etiology is unknown [6]. A
number of studies have reported abnormal cell growth and migration-related disturbances in
postmortem tissue from brains of autistic individuals [7, 8], suggesting that the etiology of
ASD involves aberrations in neurogenic processes in specific regions of the brain. The
subventricular zone (SVZ) of the lateral ventricles (LV) is one of two neurogenic niches in
the brain critical to neural proliferation, migration, and differentiation, both prenatally and
into adulthood [9–11]. The unique structure and composition of the LV-SVZ regulates
normal neurogenic functioning at various phases of development [10, 12]. Thus far, the
cellular organization, proliferative cellular activity, and molecular compostion of the LV-
SVZ region has not been examined in studies using postmortem tissue of autistic indivuals.
The extracellular glycosaminoglycan (GAG) heparan sulfate (HS) is a prominent and
integral component of the LV-SVZ microenvironment [13]. The HS proteoglycan consists
of a core protein, of which there are several families, to which GAG HS chains consisting of
variably sulfated repeating disaccharide units are attached [14]. Both the core protein and
the composition of the HS chains influence interactions with a wide variety of ligands,
including growth factors and cytokines, resulting, in brain, in modulation of cell
proliferation, differentiation, and migration [15, 16]. HS magnitude and composition are
influenced by a variety of genes [17]; are responsive to environmental/experiential events
such as oxidative stress [18], and modulate responsivity to inflammation [19]. They may
change across development [20].
The purpose of the current study was to examine and characterize the LV-SVZ in
postmortem tissue from individuals diagnosed with ASD. Specifically, the current study
evaluated an hypothesis stemming from findings in a mouse model of autism [21, 22] that
HS may be reduced in the human autistic LV-SVZ. This study examined postmortem tissue
of autism-diagnosed individuals (n = 4) and age/sex matched typically developing (TD)
controls (n = 4) from three areas of the LV-SVZ region using immunofluorescence
methodology.
2. Methods
2.1. Brain tissue samples
Frozen postmortem brain tissue samples from male autism (ADI-R confirmed) cases and
age/sex-matched controls were obtained from the Harvard Brain Tissue Resource Center and
the NICHD Brain and Tissue Bank for Developmental Disorders through the Autism Tissue
Program of Autism Speaks. Donor characteristics are presented in Table 1. Three frozen
blocks per case were excised from the dorsal lateral ventricle wall including the anterior
horn and body of the lateral ventricle. Blocks included portions of the medial caudate
nucleus and body of the corpus callosum (Fig. 1a).
Tissue blocks (2.0 cm3) from each case were sectioned on a cryostat (Leica, CM1850UV)
perpendicular to and containing the ependymal, subependymal and parenchymal zones in
the coronal plane at 10 μM. Tissue sections were mounted on Poly-L-lysine (1:5 Sigma-
Aldrich) coated glass microscope slides (VWR superfrost) and stored at −20°C.
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Slides were fixed in acetone (−20°C, 2 min) and rinsed in phosphate buffered saline (PBS)
for 5 min. Wells were created on the slide with a hydrophobic barrier pen (Vector Labs,
H-4000), tissue sections were permeabilized with Triton-X-100 (0.5%, 15 min, Fisher),
blocked with a PBS gelatin blocking solution (0.2%, 10 min), labeled with antibodies, and
cover slipped with a mounting medium containing 4′,6-diamidino-2-phenylindole (DAPI)
nuclear marker (Vector Labs, H-1200).
Antibody specificity was tested by performing incubations in the absence of primary and/or
secondary antibodies. Tissue sections, particularly those collected from older donors,
exhibited lipofuscin-like autofluorescence [23] in the absence of antibodies. Two solutions
(1% and 3%) of Sudan Black B (Sigma-Aldrich) [24] and a commercial reagent (Millipore,
2160) were tested on independent sections and assessed for autofluorescence blocking under
405nm, 488nm, and 546nm excitation on an Olympus Fluoview FV1000 laser scanning
confocal microscope. Sudan black (1%) was the most effective at blocking non-specific
autofluorescence and was used to treat all tissue sections.
For Ki67 protein and glial fibrillary acidic protein (GFAP) immunostaining, five randomly
selected slides per case were incubated with anti-GFAP (1:1000, mouse IgG, Millipore) and
anti-Ki67 (1:40, rabbit polyclonal, Millipore) for 24 hr, washed in PBS, blocked with a PBS
gelatin blocking solution, and incubated with secondary antibodies Alexa Fluor 546 goat-
anti rabbit IgG (1:400, Invitrogen) and Alexa Fluor 488 goat anti-mouse IgG (1:400,
Invitrogen) for 40 min.
For heparan sulfate and laminin (LAM) immunostaining, fifteen slides per case, each
distributed evenly throughout the antero-posterior extent of the blocks, were incubated with
anti-heparan sulfate (1:400, mouse IgM, Seikagaku Corp, 10E4) and anti-Laminin (1:1000,
rabbit IgG, Sigma-Aldrich) primary antibodies for 120 min, followed by washes in PBS and
PBS gelatin blocking solution. Sections were then incubated with secondary antibodies
Alexa Fluor 546 goat-anti rabbit IgG (1:400, Invitrogen) and Alexa Fluor 488 goat anti-
mouse IgM (1:400, Invitrogen) for 40 min.
2.3. Microscopy and Image Processing
Researchers were blind to condition at all times during microscopy, image preparation, and
quantification. Sections were imaged on an Olympus Fluoview FV1000 laser scanning
microscope mounted on an Olympus IX81 inverted microscope at the Biological Electron
Microscope Facility of the University of Hawaii. DAPI, AlexaFluor 488, and AlexaFluor
546 were excited sequentially at 405nm, 488nm, and 546nm respectively with blue diode,
green HeNe, and red HeNe lasers. Microscopy images were exported as digital TIFF image
files (1024X1024 pixels).
Images for DAPI, heparan sulfate, and laminin quantification (52–75 per case, non-
overlapping fields) were acquired using a 20X UplanApo (0.70) optical objective with 2.0X
digital zoom (fixed settings for laser power, high voltage, gain, and offset) along the entire
dorsal-ventral extent of the ependymal layer (I) of the subventricular zone.
Z-stacks (1024X1024 pixels) for co-localization of Ki67/GFAP and heparan sulfate/laminin
co-labeling were acquired with a UPLSAPO 60X oil-immersion lens (NA 1.35) at 1.0X and
2.0X zoom. Digital images were processed using Adobe Photoshop CS3 (Adobe Systems)
and ImageJ (NIH). A minor levels adjustment was applied to all TIFF images in Adobe
Photoshop.
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DAPI labeling was used to locate the layered cellular organization of the LV-SVZ and to
quantify the width of the hypocellular layer (II) of the LV-SVZ. To assess the hypocellular
width, coded TIFF images for each case were opened in ImageJ (NIH) software and five
ROI measurements from the ependymal layer (1) to the astrocytic ribbon layer (III) of the
LV-SVZ were averaged.
To assess cellular proliferation in the LV-SVZ, the mean number of Ki67+ cells was
estimated by manually counting the number of Ki67+ cells in ten microscopic objective
fields along the dorsal-ventral extent of the LV-SVZ for fifteen tissue sections per case.
To assess the localization and quantity of heparan sulfate and laminin immunofluorescence
in different layers of the LV-SVZ, coded images were imported into ImageJ (NIH) software
and converted into RGB stacks. The polygon selection tool was used to outline regions of
interest (ROI) including the following areas of the LV-SVZ: a standardized 250 μM width
area of the LV-SVZ extending from the ependymal layer (I) into layers (III) and (IV), the
hypocellular layer (II) area of the LV-SVZ, and remaining layers (III) and (IV) combined of
the LV-SVZ. This dimension (250 μM) was selected as a standard medio-lateral width
because it includes the range of variable LV-SVZ widths demonstrated previously [25].
Large blood vessels and choroid plexus were omitted from fluorescence quantification
measurements. Area, integrated density, and mean gray value were collected for the ROI as
well as for three background areas per channel. Together, these were used to calculate
corrected total fluorescence values [Integrated density − (area of selected zone × mean
fluorescence of background images)] according to previously published methods for each
image [26].
2.5. Statistical Analysis
Mean corrected total fluorescence values for the 250μM, hypocellular region as well as
hypocellular layer width and Ki67+ cell counts were compared with two-way analyses of
variance (ANOVA) with condition (Autism vs. Control) and Age as main factors. When
main effects or interactions were found, Bonferroni post hoc comparisons were performed to
assess significant differences between conditions at each age group. Unpaired t-tests were
used to compare mean fluorescence and cell count values across all ages. A probability of p
< .05 was adopted as the level of statistical significance.
3. Results
3.1. DAPI localization of the LV-SVZ in autistic and TD postmortem tissue
DAPI nuclear labeling guided the localization of the layered human LV-SVZ for autism-
diagnosed and control tissue sections (Fig. 1b). Autism-diagnosed tissue did not differ from
TD samples in the characteristic layered organization of the human LV-SVZ. In coronal
sections, the area bordering the lateral wall of the lateral ventricles consisted of a one to two
cell DAPI+ cell layer corresponding to the ependymal layer (I). Adjacent to ependymal layer
was the hypocellular layer (II), which was mostly devoid of DAPI+ cells except for a few
displaced ependymal cells. DAPI+ cells were present in the layer (III) that has been
characterized to consist of a continuous band of astrocytes and the layer (IV) that blended
into the adjoining parenchyma [10, 12]. Since DAPI staining reveals a defined hypocellular
layer (II) largely devoid of positive cells, we investigated whether the hypocellular gap
width differed between autism and control samples (Fig. 1b, c). The hypocellular gap width
did not significantly differ between autism and TD samples; however, the hypocellular gap
width was larger for older tissue samples compared to younger samples [t(298) = 9.76, p<.
0001] (Fig. 1b, c).
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The mean number of Ki67+ proliferating cells were increased in tissue from the autistic
member of the 5–6 year-old pair [p<.001] reflecting an increase in actively mitotic cells,
with no notable differences between pair members thereafter (Fig. 2a). Ki67+ proliferating
cells were observed on the ependymal wall, within the hypocellular layer (II), and within
layers (III) and (IV) of the LV-SVZ (Fig. 2b, c). We examined the co-localization of Ki67
and GFAP and observed Ki67+/GFAP+ cells near the ependymal wall of the youngest
autistic sample (Fig. 2d), suggestive of a distinct type of proliferating cell with possible stem
cell properties [10].
3.3. Examination of extracellular matrix component HS
HS immunofluorescence was more localized to the hypocellular layer (II) region of the LV-
SVZ for autism and typically developing control cases [t(584) = 6.67, p<.0001] (Fig. 3a).
When the entire section, from the ventricle wall to a standard distance of 250 μm was
analyzed, HS immunofluorescence in tissue from typically developing control individuals
declined systematically with increasing age (Fig. 3b). This age-related decline in HS
immunofluorescence was less marked in tissue from autistic individuals and HS levels were
sharply lower than those of the paired TD-control value at each of the youngest age-matched
pairs [p<.001] (Fig. 3b, c, d). In the 60-year old pair, HS immunofluorescence levels were
very low for both the autistic and the TD members of the pair (Fig 3e, f). Over all 4 pairs,
this autism – TD difference was significant [F(1,289) = 46.11, p<.0001]. This consistent
decrease in HS with age for the TD group reflected age-related changes localized to the
hypocellular layer (Fig. 4a, b, c).
3.4. Examination of basement membrane component LAM immunofluorescence
The concentration of LAM (amount per unit area) was significantly higher in the
hypocellular layer (II) than in layers (III) and (IV) [t(584) = 13.22, p<.0001] (Fig. 4a),
although LAM-positive capillaries were present in the latter; supporting the functional
localization of LAM to the basement membrane of the LV-SVZ [27]. LAM fluorescence in
tissue from autistic individuals was different from that of the TD pair-members [F(1,383) =
8.27, p=.004] (Fig. 4b). However, these differences were not consistent across condition or
age.
3.5. HS/LAM and LAM/GFAP co-localization
In the hypocellular zone of autism-diagnosed and TD cases, the extracellular matrix
consisted of LAM-dense zones corresponding to fractone or fractone-like basal lamina
structures [28] surrounded by GFAP+ astrocytic processes extending from the characteristic
astrocytic ribbon layer in the human LV-SVZ [12] (Fig. 6a). In the hypocellular layer (II)
area of samples from young, young-adult, and middle-aged autism and TD individuals, HS
frequently co-localized with LAM (Fig. 6b).
4. Discussion
In this first report of findings from examination of postmortem tissue from the LV-SVZ
region of autistic and TD individuals, HS in the LV-SVZ was reduced in tissue from brains
of younger autistic individuals, relative to TD controls. Tissue from the 60-year old autistic
individual did not display reduced HS relative to its TD pair-member. However, HS levels
declined sharply and systematically with increasing age for the 4 TD individuals, consistent
with previous findings in both human and rodent brain tissue [29–31] and HS was extremely
low in the 60-year old TD pair member, with levels converging for the two members of this
pair. Thus, the lack of a substantial autistic-TD difference in this oldest pair appears to
reflect this decline in HS with age, in the LV-SVZ for TD individuals.
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Increased cellular proliferation (Ki67+) was also noted in tissue from the youngest autistic
individual, only, with no pair differences thereafter. This age-related increased proliferation
is interesting in the context of a well-documented enhancement of prefrontal cortical volume
in autistic children between about 1–2 and 10 years of age, with subsequent normalization
[7, 32]. Sanai et al. have reported that in young human brains a substantial offshoot of the
LV-SVZ rostral migratory stream is directed at the prefrontal cortex [33]. However,
additional research needs to determine whether alternations in the LV-SVZ underlie the
cortical volume differences reported in autism. That this increase in Ki67+ cells was found
in conjunction with reduced HS levels is compatible with reports suggesting that some HS
configurations may be associated with reductions, rather than increases in neurogenesis [34].
In the current study, the monoclonal antibody for HS recognized enriched N- sulfated motifs
of the disaccharide chain [35]. HS chains differ in a host of posttranslational modifications,
including sulfation, to produce what has been called “the most information dense molecules
found in nature” [36]. Thus, these differences in all but the oldest autistic-TD pair could
reflect a specific reduction in N- sulfated HS in autistic individuals, rather than a general HS
reduction. Given the many roles that HS proteoglycans play in the development of virtually
every body organ, the relative lack of robust anatomical or physiological differences for
autistic individuals may suggest HS changes that are specific to the brain, or to the LV-SVZ,
or that involve only some particular components of the “heparanome” [37]. Brain infusions
of the closely related glycosaminoglycan heparin sulfate have been reported to modulate
learning and memory in an age-dependent manner [38, 39]; suggesting that manipulation of
endogenous GAGs or administration of exogenous GAGs may modulate cognitive processes
and behavior and might provide a potential treatment approach for some of the behavioral
aberrations associated with ASD.
It is notable that both autistic children, and BTBR T+tf/J mouse model of autism, show
substantially reduced levels of sulfates in peripheral tissues [40–46]; potentially interesting
in terms of the possibility of a specific reduction in N-sulfated HS, and raising the
possibility that the HS differences measured here reflect under-sulfation (ie.[47]), rather than
a general reduction in HS. In addition, findings of increased cell proliferation only in LV-
SVZ tissue from the 5-year-old autistic individual suggests that HS composition may vary
with age. Clearly, additional work on the composition of HS and HS proteoglycans in the
LV-SVZ in autistic individuals is needed to clarify these questions, and to suggest particular
downstream mechanisms that might be altered because of these HS changes and their
interactions with growth and guidance factors in the LV- SVZ [15]. In the hypocellular layer
(II) area, HS frequently co-localized with LAM suggesting that the latter may be an
important basement membrane substrate for HS activity. However, LAM levels, while
consistently different between members of age-pairs, did not show a consistent direction of
difference for tissue from autistic individuals.
Post-mortem histopathological examination results were available for two of the four
autism-diagnosed individuals in this study. Both showed altered neural anatomy and cellular
proliferation. The five-year-old autistic individual showed cortical dysplasia in parietal and
occipital lobes and flocculonodular dysplasia in the cerebellum (ATP Neuropath Report).
The sixty year old displayed frontal and entorhinal cortex focal dysplasia as well as cellular
and morphological disturbances of the dentate gyrus and cerebellum and region-dependent
increases and decreases in neuronal volume and density (ATP Neuropath Report). These
brain changes are similar to those found in previously analyzed brain tissue: Indeed the 60-
year old autistic individual was part of the cohort reported by Wegiel et al. [8] and suggest
that HS interactions with growth and guidance factors may be involved. Nonetheless, given
that histopathological examinations are not available for the other samples, any specific
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connection between N-sulfated HS levels and development of the brain in autistic
individuals remains speculative.
The responsivity of HS to potentially relevant genetic and environmental effects [19]
provides an additional rationale for attempts to determine if, and how, perturbations of these
dynamic systems are involved in autism. Insofar as HS, or other mechanisms in the LV-
SVZ, are factors in the development of autism, the search for genetic signatures related to
autism might be particularly appropriate in this area. In particular, the concept of genetic
“vulnerability” to environmental/experiential events implied in an interactive view of the
etiology of autism might be examined specifically in the context of altered LV-SVZ gene
expression related to HS and the growth and guidance factors that it influences.
Finally, the hypothesis that HS in the LV-SVZ may be altered in autistic individuals was
based on, and reflects, reports of reduced HS in the LV-SVZ in BTBR T+tf/J mice, which
show autism-relevant changes in each of the 3 symptom-clusters by which autism is defined
[21, 22, 48]. The hypothesis also agrees with findings that conditional Ext1 knockout mice,
lacking HS postnatally, show a deficit in social behaviors and an increase in stereotyped
behaviors [49]; and with reports of genetic conditions impacting HS in autistic individuals
[50]. A substantial proportion of the 25+ genes regulating HS [51] have been associated with
autism: In particular, genes regulating HS synthesis (EXT1, EXT2: [52, 53]), and
disaccharide residue sulfation/deacetylation (HS3ST5, HS3ST6, NDST4: [52, 54, 55]) have
shown autism related variants. BTBR T+tf/J mice also show a variety of physiological
differences from more social strains such as the C57BL/6J, including neuroanatomic
abnormalities; changes in neurodevelopmental proteins; enhanced systemic glucocorticoids;
and changes in immune systems that provide potential links to findings reported in autistic
individuals (reviewed in [48]). To this burgeoning evidence that the BTBR T+tf/J mouse can
serve as a particularly appropriate and specific animal model for autism, the present study
adds predictive validity that a particular, area-localized change in an important brain
molecule, noted for the BTBR T+tf/J mouse, is also found in autistic individuals. This
reduction in HS is potentially related to a number of the neuroanatomical [56] and immune
system [57] changes noted in autism. The BTBR T+tf/J mouse, as well as other mouse
strains with alterations of this system, may provide a highly appropriate model for
examining changes in the heparanome and their effects on the brain and behavior.
Our finding that n-sulfated HS in the LV-SVZ appears to be reduced in brains of all but
elderly autistic individuals, compared to TD age- and sex-matched pair members, suggests
that HS may contribute to the aberrations in brain development and behavior that are seen in
autism. These findings suggest the value of detailed analyses of HS content and composition
in the LV-SVZ, as well as determinations of potential changes in gene expression in this
area, for autistic vs. TD individuals at different ages.
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• We examine the neurogenic subventricular zone (SVZ) in postmortem autism
tissue.
• Decreased heparan sulfate immunofluorescence in autism SVZ tissue.
• Increased cellular proliferation in the 5 yr old autism-diagnosed SVZ tissue.
• Aberrant extracellular matrix function in the SVZ may be a biomarker for
autism.
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Cellular organization in the human subventricular zone of the lateral ventricles. (a)
Representative excised tissue block from a coronal section containing the LV-SVZ (b)
Layered morphology of human LV-SVZ. I–IV label ependymal, hypocellular gap [Hypo.],
astrocytic ribbon and transitional zone layers, respectively. (c) Hypocellular layer width
similar across conditions, but significantly increased in tissue derived from 39 to 60 year
olds compared to 5 to 21 year olds (mean+sem, **P<.01). (d) Hypocellular gap width
measurement of young and old autism and typically developing control samples. Scale bars:
30 μm. LV- lateral ventricle. AU- arbitrary units.
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Increased proliferation in the LV-SVZ in youngest autism case (AN08873). (a) Autism-
diagnosed 5 year old sample shows increased number of proliferating cells compared to age-
matched control sample (mean+sem, **P<.01). (b) Ki67+ cells (arrow) were present in the
hypocellular layer of 5 yr old autism case and contained GFAP+ astrocytic processes. (c)
Additionally, Ki67+ cells were viewed on the ependymal wall and (d) dashed box denotes
higher-magnification z-stack showing co-localization of Ki67 and GFAP in tissue from the 5
yr old autism case. Scale bars: 30 μm. LV- lateral ventricle. Scale bars: 30 μm. LV- lateral
ventricle. AU- arbitrary units.
Pearson et al. Page 13














HS is reduced in the LV-SVZ of autistic individuals and decreases by age in typically
developing controls. (a) HS is localized to the hypocellular region compared to layers 3 & 4
(mean+sem, **P<.01). (b) 250 μm into the LV-SVZ, HS is decreased overall in autism-
diagnosed samples compared to controls; young (5–6) and young adult (20–21) autism-
diagnosed samples significantly lower than TD controls (mean+sem, **P<.01). (c, d, e, f)
HS is decreased in young (5–6) but not older (60) autism-diagnosed samples. Scale bars: 30
μm. LV- lateral ventricle. AU- arbitrary units.
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HS in the hypocellular layer of the LV-SVZ is decreased in autistic individuals and
decreases by age in typically developing controls (a) HS immunoreactivity is elevated lateral
to ventricular wall in young and young adult typically developing controls but not autism-
diagnosed samples (mean+sem, **P<.01). (b, c) HS is enriched in hypocellular layer (layer
II) of the young TD control, but not ASD sample. Scale bars: 30 μm. LV- lateral ventricle.
AU-arbitrary units.
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Laminin is abundant in the hypocellular layer. (a) LAM is enriched in the hypocellular layer
across conditions compared to layers 3 and 4 of the SVZ. (b) Autism samples show complex
age-specific changes in LAM immunoreactivity in the LV-SVZ. (c, d, e, f) Confocal
micrographs demonstrating abundant LAM glycoprotein in the hypocellular layer and
capillaries (arrow) of 60 yr old control and autism samples. Scale bars: 30 μm. LV- lateral
ventricle. AU- arbitrary units.
Pearson et al. Page 16














Astrocytic processes interact with laminin and heparan sulfate is localized to basement
membrane laminin in the hypocellular layer. (a) Maximal projection Z stack displays
proximal association of hypocellular LAM and astrocytic processes in the hypocellular,
subependymal layer. (b) LAM and HS co-labeling in the extracellular matrix of hypocellular
layer. Scale bars: 30 μm. LV- lateral ventricle. AU- arbitrary units.
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